Citi Upgrades GlaxoSmithKline (GSK) to Buy
Tweet
Share
E-mail
Get Alerts GSK Hot Sheet
Price: $40.86 -0.92%
Rating Summary:
8 Buy, 13 Hold, 3 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 11 | New: 14
Rating Summary:
8 Buy, 13 Hold, 3 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 11 | New: 14
Join SI Premium – FREE
Citi upgraded GlaxoSmithKline (NYSE: GSK) from Neutral to Buy.
For an analyst ratings summary and ratings history on GlaxoSmithKline click here. For more ratings news on GlaxoSmithKline click here.
Shares of GlaxoSmithKline closed at $43.34 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Citi Upgrades United Microelectronics Corp (2303:TT) (UMC) to Buy 'with limited downside'
- Piper Sandler Upgrades SmartFinancial (SMBK) to Overweight 'on Risk/Reward Dynamic for Clean Bank Under TBVPS'
- BofA Securities Upgrades Tesla (TSLA) to Buy on wind up of positive catalysts
Create E-mail Alert Related Categories
UpgradesRelated Entities
CitiSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
